293480.KS
Hana Pharm Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 8,420.00
−1.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 247.3B | 239.5B | 225.3B | 224.5B | 210.8B |
| Cost of Revenue | 95.3B | 93.1B | 84.0B | 84.9B | 79.6B |
| Gross Profit | 152.0B | 146.4B | 141.3B | 139.6B | 131.2B |
| Operating Expenses | |||||
| R&D Expense | 14.8B | 15.3B | 9.0B | 7.4B | 4.7B |
| SG&A Expense | 70.9B | 57.9B | 56.7B | 55.3B | 48.2B |
| General & Admin Expense | 19.7B | 28.3B | 29.5B | 29.3B | 28.2B |
| Selling & Marketing Expense | 25.0B | 29.6B | 27.1B | 25.9B | 20.0B |
| Other Expenses | 40.0B | 47.3B | 50.5B | 49.9B | 47.2B |
| Total Operating Expenses | 123.3B | 120.5B | 116.1B | 112.6B | 100.1B |
| Cost and Expenses | 218.7B | 214.0B | 200.2B | 197.4B | 179.7B |
| Operating Income (EBIT) | 28.6B | 25.9B | 25.2B | 27.0B | 31.2B |
| Non-Operating | |||||
| Interest Income | 193.3M | 195.5M | 264.2M | 274.9M | 270.0M |
| Interest Expense | — | — | — | — | 585.7M |
| Net Interest Income | 193.3M | 195.5M | 264.2M | 274.9M | (315.6M) |
| Other Non-Op Income/Expense | (566.9M) | (7.6B) | 239.9M | 875.5M | (452.4M) |
| Non-Operating Income (excl Interest) | — | — | — | — | (133.3M) |
| EBT (Pre-Tax Income) | 28.0B | 18.4B | 25.4B | 27.9B | 30.7B |
| Income Tax Expense | 10.6B | 9.6B | 4.1B | 5.6B | 6.4B |
| Bottom Line | |||||
| Net Income | 17.5B | 8.8B | 21.3B | 22.3B | 24.3B |
| Earnings from Cont. Ops | 17.5B | 8.8B | 21.3B | 22.3B | 24.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 17.5B | 8.8B | 21.3B | 22.3B | 24.3B |
| Per Share | |||||
| Basic EPS | ₩983 | ₩507 | ₩1,230 | ₩1,291 | ₩1,405 |
| Diluted EPS | ₩982 | ₩507 | ₩1,228 | ₩1,291 | ₩1,405 |
| Revenue Per Share | ₩13,954 | ₩13,476 | ₩13,026 | ₩12,975 | ₩12,188 |
| Shares | |||||
| Basic Shares Outstanding | 17.7M | 17.8M | 17.3M | 17.3M | 17.3M |
| Diluted Shares Outstanding | 17.7M | 17.8M | 17.3M | 17.3M | 17.3M |
| Profitability Metrics | |||||
| EBITDA | 41.6B | 37.0B | 32.9B | 34.7B | 37.7B |
| D&A | 13.0B | 11.0B | 7.7B | 7.6B | 6.4B |
| EBIT | 28.6B | 25.9B | 25.2B | 27.0B | 31.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026